Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil

Autor(es):Mostrar menos -

de Melo, Andreia Cristina ^[1] ; de Sa, Vanessa Karen ^[2] ; Sternberg, Cinthya ^[1] ; Olivieri, Eloisa Ribeiro ^[3] ; da Cunha, Isabela Werneck ^[3] ; Fabro, Alexandre Todorovic ^[2] ; Carraro, Dirce Maria ^[3] ; de Barros e Silva, Milton Jose ^[1] ; Pimenta Inada, Haynna Kimie ^[1] ; de Mello, Evandro Sobrosa ^[4] ; Soares, Fernando Augusto ^[3] ; Takagaki, Tereza ^[5] ; Ferreira, Carlos Gil ^[1] ; Capelozzi, Vera Luiza ^[2]

Afiliação do(s) autor(es)

^[1] Natl Canc Inst, Rio De Janeiro - Brazil

^[2] Univ Sao Paulo, Fac Med, Dept Pathol, BR-01296903 Sao Paulo, SP - Brazil

^[3] AC Camargo Canc Ctr, Ctr Int Pesquisa, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Div Pulm, Canc Inst State Sao Paulo, BR-01296903 Sao Paulo, SP - Brazil

^[5] Univ Sao Paulo, Div Pulm, Heart Inst InCor, BR-01296903 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ONCOLOGY; v. 89, n. 3, p. 175-186, 2015.
• Citações Web of Science: 10

Resumo

Aim: To show additional prognostic information about the mutational profile and new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification of adenocarcinoma (ADC) in patients without epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatments. Methods: In human lung ADC patients (n = 125), including 24 lepidic, 67 acinar, 23 papillary, and 11 solid predominant subtypes, EGFR and KRAS were sequenced, and anaplastic lymphoma kinase (ALK) rearrangements were screened using fluorescence in situ hybridization (FISH). Results: EGFR was mutated in 21.6% of patients with 19.57% showing a mean expression. The most frequent EGFR mutation was a deletion in exon 19, followed by an L858R amino acid substitution in exon 21. KRAS was mutated in 26.4% of patients with 50% displaying mean expression. ALK rearrangement was detected in 6 patients (4.8%). Predominant acinar ADC was strongly associated with EGFR and KRAS mutation. Clinical stage, lymph node metastases, and EGFR mutation in exon 18 showed a significant difference in disease-free and overall survival, but only a trend significance for EGFR and KRAS mutations. Multivariate analysis revealed that men aged >71 years, with a history of smoking (<72 packs/year), clinical stage I/II, and acinar histologic subtype presented better survival than women aged <= 71 years, with a history of smoking (>72 packs/year), and having a predominant solid ADC and EGFR mutation in exon 18. Conclusions: These results indicate that the mutational profile and new IASLC/ATS/ERS classification provide additional prognostic information about lung ADC. (C) 2015 S. Karger AG, Basel (AU)

• Processo FAPESP: 11/52095-0 - Avaliação da frequência das mutações EGFR, KRAS e EML4-ALK em adenocarcinomas e seus subtipos e impacto da expressão das hialuronidases e sintases do ácido hialurônico nas lesões pré-neoplásicas pulmonares
• Beneficiário: Vera Luiza Capelozzi
• Modalidade de apoio: Auxílio à Pesquisa - Regular